(Q43182471)

15 November 2017

title

Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation (English)

1 reference

15 November 2017

1 reference

P Ravva

1

1 reference

15 November 2017

M R Gastonguay

2

1 reference

15 November 2017

J L French

3

1 reference

15 November 2017

T G Tensfeldt

4

1 reference

15 November 2017

H M Faessel

5

1 reference

15 November 2017

language of work or name

English

0 references

publication date

27 January 2010

1 reference

Clinical Pharmacology & Therapeutics

15 November 2017

published in

1 reference

15 November 2017

volume

87

1 reference

15 November 2017

issue

3

1 reference

15 November 2017

page(s)

336-344

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2009.282

15 November 2017

exact match

0 references

cites work

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Population pharmacokinetic analysis of varenicline in adult smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Diagnosing model diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: indirect response and probabilistic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Issues in the analysis of repeated categorical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Estimates of global mortality attributable to smoking in 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

7 January 2021

Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

7 January 2021

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

7 January 2021

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

7 January 2021

Determinants of quitting smoking

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

7 January 2021

Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

7 January 2021

Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.282

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.282

1 reference

Dimensions Publication ID

15 November 2017

1008433849

0 references

1 reference